Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Antonia
Antonia Costa Bauza, Palma De Mallorca ES
| Patent application number | Description | Published |
|---|---|---|
| 20110172194 | COMPOSITION OF DIALYSIS LIQUID COMPRISING CRYSTALLISATION INHIBITOR SUBSTANCES - This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallisation. | 07-14-2011 |
Antonia Costa Bauza, Sant Joan ES
| Patent application number | Description | Published |
|---|---|---|
| 20090035232 | FIXED-DOSE ASSOCIATION OF PHYTATE AND ZINC - The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallisation of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallisation of hydroxyapatite in humans. | 02-05-2009 |
Antonia Costa-Bauza, Palma De Mallorca Baleares ES
| Patent application number | Description | Published |
|---|---|---|
| 20090203650 | USE OF PHYTATE AS AGENT INHIBITING DISSOLUTION OF CRYSTALS OF CALCIUM SALTS FOR THE PREVENTION OF OSTEOPOROSIS - The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture of functional foods, dietetic supplements, vitamin supplements, nutritional supplements, food supplements, or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts. | 08-13-2009 |
Antonia Gross-Tarakji, Nussloch DE
| Patent application number | Description | Published |
|---|---|---|
| 20100070946 | Providing Supplier Relationship Management Software Application as Enterprise Services - Methods and apparatus, including systems and computer program products, for a services architecture design that provides enterprise services having supplier relationship management functionality at the level of an enterprise application. The design includes a set of service operations, process components, and optionally deployment units. Suitable business objects are also described. | 03-18-2010 |
| 20110307398 | Managing Consistent Interfaces for Request for Information, Request for Information Response, Supplier Assessment Profile, Supplier Questionnaire Assessment, and Supplier Transaction Assessment Business Objects across Heterogeneous Systems - A business object model, which reflects data that is used during a given business transaction, is utilized to generate interfaces. This business object model facilitates commercial transactions by providing consistent interfaces that are suitable for use across industries, across businesses, and across different departments within a business during a business transaction. In some operations, software creates, updates, or otherwise processes information related to a request for information, a request for information response, a supplier assessment profile, a supplier questionnaire assessment, and/or a supplier transaction assessment business object. | 12-15-2011 |
Antonia Lopez-Girona, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090297528 | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders - The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits. The present invention relates to screening assays that use novel and known substrate-targeting subunits of ubiquitin ligases to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel and known ubiquitin ligases which modulate activity of the novel and known ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative and differentiative disorders. | 12-03-2009 |
Antonia Macciouccu, Roma IT
| Patent application number | Description | Published |
|---|---|---|
| 20080199962 | Qualitative Assay of Extra-Virgin Olive Oils - A methodology that enables introduction of an innovative assay for evaluating the extra-virgin olive oil (EOO), based upon the quantification of the main components of the saponifiable and non-saponifiable fractions of EOOs and upon its total antioxidizing power. | 08-21-2008 |
Antonia Orsi, Cambridgeshire GB
| Patent application number | Description | Published |
|---|---|---|
| 20120034193 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS - An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health. | 02-09-2012 |
Antonia Orsi, Godmanchester GB
| Patent application number | Description | Published |
|---|---|---|
| 20110190249 | THERAPEUTIC METHODS AND USES OF SAPOGENINS AND THEIR DERIVATIVES - The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment. | 08-04-2011 |
Antonia Periclou, Jersey City, NJ US
| Patent application number | Description | Published |
|---|---|---|
| 20100028427 | IMMEDIATE RELEASE FORMULATIONS OF 1-AMINOCYCLOHEXANE COMPOUNDS, MEMANTINE AND NERAMEXANE - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 02-04-2010 |
| 20110236439 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 09-29-2011 |
| 20120004318 | MODIFIED RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS - The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment. | 01-05-2012 |
Antonia Urmanova, Zwolle NL
| Patent application number | Description | Published |
|---|---|---|
| 20100016503 | POWDER COATINGS & USES THEREOF - The invention relates to a binder comprising crosslinker and branched, partially defunctionalized, acid-functional polyester based on: a. At least one multi-functional component; b. At least one di-functional component that is reactive towards a functional group on the multi-functional component; and c. At least one mono-functional component; wherein the polyester has a glass transition temperature of 40° C. or greater. | 01-21-2010 |
| 20100152393 | BRANCHED POLYESTER CONTAINING POWDER COATING COMPOSITION - The invention relates to binder comprising a crosslinker that is reactive with acid-functional polyester and a branched, partially defunctionalized acid-functional polyester, wherein the polyester is based on: a. At least one multi-functional component that is either carboxyl-functional, hydroxyl-functional or carboxyl- and hydroxyl-functional; b. At least one di-functional component that is reactive towards a functional group on the multi-functional component; and c. At least one mono-functional component; wherein the multi-functional component does not contain a tertiary carboxylic functionality and at least 50% of the acid-derived groups originate from an aromatic acid. | 06-17-2010 |